91 related articles for article (PubMed ID: 8015765)
21. DNA content and S-phase fraction in epithelial ovarian cancer: what information do they really add?
Braly P
Gynecol Oncol; 1998 Oct; 71(1):1-2. PubMed ID: 9784311
[No Abstract] [Full Text] [Related]
22. Gene-expression profiling in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Cannistra SA
Nat Clin Pract Oncol; 2008 Oct; 5(10):577-87. PubMed ID: 18648354
[TBL] [Abstract][Full Text] [Related]
23. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.
Lu L; Katsaros D; de la Longrais IA; Sochirca O; Yu H
Cancer Res; 2007 Nov; 67(21):10117-22. PubMed ID: 17974952
[TBL] [Abstract][Full Text] [Related]
24. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy.
Zhang HY; Zhang PN; Sun H
Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):81-6. PubMed ID: 19540648
[TBL] [Abstract][Full Text] [Related]
25. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
26. Early events in ovarian oncogenesis.
Cvetkovic D
Reprod Biol Endocrinol; 2003 Oct; 1():68. PubMed ID: 14577833
[TBL] [Abstract][Full Text] [Related]
27. Molecular and biologic factors in the pathogenesis of ovarian cancer.
Berek JS; MartÃnez-Maza O
J Reprod Med; 1994 Apr; 39(4):241-8. PubMed ID: 8040839
[TBL] [Abstract][Full Text] [Related]
28. Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer.
Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Franklin J; Friedlander M; Andrews L
Psychooncology; 2005 Apr; 14(4):249-61. PubMed ID: 15386771
[TBL] [Abstract][Full Text] [Related]
29. Analysis of allelic imbalance on chromosome 17p13 in stage I and stage II epithelial ovarian cancers.
Wiper DW; Zanotti KM; Kennedy AW; Belinson JL; Casey G
Gynecol Oncol; 1998 Oct; 71(1):77-82. PubMed ID: 9784323
[TBL] [Abstract][Full Text] [Related]
30. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer.
Howells RE; Redman CW; Dhar KK; Sarhanis P; Musgrove C; Jones PW; Alldersea J; Fryer AA; Hoban PR; Strange RC
Clin Cancer Res; 1998 Oct; 4(10):2439-45. PubMed ID: 9796976
[TBL] [Abstract][Full Text] [Related]
31. Molecular biology of human ovarian cancer.
Chow SN; Chien CH; Chen CT
Int Surg; 1996; 81(2):152-7. PubMed ID: 8912082
[TBL] [Abstract][Full Text] [Related]
32. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer.
Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Puopolo M; Schwartz P; Yu H
Gynecol Oncol; 2006 Dec; 103(3):990-5. PubMed ID: 16859738
[TBL] [Abstract][Full Text] [Related]
33. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk.
Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2566-71. PubMed ID: 18086759
[TBL] [Abstract][Full Text] [Related]
34. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas.
Lu KH; Weitzel JN; Kodali S; Welch WR; Berkowitz RS; Mok SC
Cancer Res; 1997 Feb; 57(3):387-90. PubMed ID: 9012461
[TBL] [Abstract][Full Text] [Related]
35. Applications of molecular epidemiology to head and neck cancer.
Hart TC
Otolaryngol Clin North Am; 1997 Feb; 30(1):21-34. PubMed ID: 8995134
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
[TBL] [Abstract][Full Text] [Related]
37. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
38. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
39. The C19007T polymorphism of ERCC1 and its correlation with the risk of epithelial ovarian and endometrial cancer in Korean women. A case control study.
Jo H; Kang S; Kim SI; Kim JW; Park NH; Song YS; Park SY; Kang SB; Lee HP
Gynecol Obstet Invest; 2007; 64(2):84-8. PubMed ID: 17314486
[TBL] [Abstract][Full Text] [Related]
40. The unique characteristics of ovarian carcinogenesis in the adolescent and young adult population.
Gibbon DG; Diaz-Arrastia C
Semin Oncol; 2009 Jun; 36(3):250-7. PubMed ID: 19460582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
